Sign in Subscribe
Cybernet Data Systems Inc.

Sunesis Pharmaceuticals Repays Debt, Reports Preliminary Financial Figures

Strategic Insights

— 1 min read

Sunesis Pharmaceuticals, a biopharmaceutical company, has paid off its outstanding debt and reported preliminary financial figures for the second quarter of 2020. The company has executed a payoff letter to repay approximately $5.7 million to Silicon Valley Bank, terminating all commitments and obligations under its term loan agreement. As of June 30, 2020, Sunesis estimates its cash and cash equivalents to be approximately $17.7 million, excluding restricted cash of $5.5 million. This payment marks a significant step in the company's financial restructuring and positions it to focus on its core business.

Key Takeaways:

  • Sunesis Pharmaceuticals has repaid its outstanding debt of approximately $5.7 million to Silicon Valley Bank, as per the payoff letter executed on July 28, 2020.
  • The company's preliminary unaudited financial figures for the second quarter of 2020 show an estimated cash and cash equivalents of $17.7 million, excluding restricted cash of $5.5 million.
  • The payoff letter terminates all commitments and obligations under the term loan agreement dated April 26, 2019, as amended.
  • Sunesis has filed a preliminary prospectus supplement with the SEC on July 28, 2020, disclosing the company's financial information.
  • The estimated cash and cash equivalents as of June 30, 2020, exclude restricted cash of $5.5 million.
  • The preliminary financial figures do not present all necessary information for a complete understanding of Sunesis's financial condition as of June 30, 2020, or its results of operations for the three and six months ended June 30, 2020.

Statistics:

  • The outstanding debt repaid by Sunesis Pharmaceuticals amounts to approximately $5.7 million.
  • The estimated cash and cash equivalents as of June 30, 2020, are $17.7 million, excluding restricted cash.
  • The restricted cash as of June 30, 2020, is estimated to be $5.5 million.
  • The term loan agreement was dated April 26, 2019, and has been amended.

Sources:

  • Sec.gov - Sunesis Pharmaceuticals, Inc.'s Form 8-K filing on July 28, 2020.
  • Sec.gov - Sunesis Pharmaceuticals, Inc.'s Form 10-Q filed with the SEC on May 7, 2020.
  • Sec.gov - Current Report on Form 8-K filed by Sunesis Pharmaceuticals, Inc. on April 29, 2019.

Read more